Pulmonary rehabilitation improves functional outcomes and quality of life in post-SARS-CoV-2 mild-to-moderate infection patients: a pilot study

• Published in: Monaldi archives for chest disease Vol. 94; no. 1
• Main Authors: Levi, Guido, Scaramozzino, Marco Umberto, Cavallo, Stefania, Castignini, Giuliano, Bezzi, Michela, Pini, Laura, Nania, Frank, Sheenam, Sheenam
• Format: Journal Article
• Language: English
• Published: Italy PAGEPress Publications 04.04.2023
• Subjects: Case-Control Studies; COVID-19; Dyspnea - physiopathology; Humans; physical activity; Pilot Projects; Pulmonary Disease, Chronic Obstructive - physiopathology; pulmonary rehabilitation; Quality of Life; SARS-CoV-2
• ISSN: 1122-0643; 2532-5264
• DOI: 10.4081/monaldi.2023.2524

SARS-CoV-2 infection impairs functional outcomes and quality of life, even in its mild-to-moderate form. Therefore, it is appropriate to draw attention to the role played by respiratory rehabilitation and physiotherapists in the pulmonary rehabilitation process that post-SARS-CoV-2 patients must undergo. We enrolled 80 patients in a prospective case-control study; 40 cases (mild-to-moderate post-SARS-CoV-2 infection patients) and 38 control subjects (i.e., patients affected by other respiratory diseases) completed the same full pulmonary rehabilitation cycle. 6-minute walking distance, Borg category-ratio 10 scale, modified Medical Research Council (mMRC) dyspnea scale, European quality of life 5-dimensions-3-level (EuroQoL EQ-5D-3L) questionnaire, Barthel scale, arterial blood gas test, and peripheral oxygen saturation were compared for all patients before and after rehabilitation. All patients experienced significant improvements in all parameters analyzed, except for the arterial blood gas test. Results were similar for both groups; in particular, both groups experienced improvements in the mMRC scale, EuroQoL EQ-5D-3L questionnaire, Barthel scale, and 6-minute walking distance. Pulmonary rehabilitation appears to improve exercise tolerance, dyspnea, and quality of life in patients recovering from a mild-to-moderate SARS-CoV-2 infection. Further studies are needed on a larger sample size population to validate these results.